Setting the cutoffs (based on the percentage of abnormal nuclei among all nuclei scored) as 10% for homozygous and 40% for heterozygous deletion, Reid and colleagues identified 17% of untreated primary prostate cancers exhibiting heterozygous or homozygous deletion of PTEN[11]. The gene discussed is PTEN; the disease is Familial prostate cancer.